+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Oral Anorexiant Drug Market - Global Forecast 2026-2032- Product Image
Oral Anorexiant Drug Market - Global Forecast 2026-2032- Product Image
Sale

Oral Anorexiant Drug Market - Global Forecast 2026-2032

  • Report

  • 188 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6148200
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Oral Anorexiant Drug Market is projected to reach USD 768.43 Million in 2026. It is expected to continue growing at a CAGR of 6.03%, reaching USD 1.09 Billion by 2032.

Oral Anorexiant Drugs: Executive Summary and Strategic Context

Oral anorexiant drugs are prescription medicines intended to reduce appetite or influence satiety and related metabolic pathways. Their development and use sit at the intersection of obesity care, chronic-disease management, behavioral health, primary care, and pharmaceutical regulation. Strategic assessment should therefore consider clinical evidence, safety monitoring, patient selection, adherence, access, and integration with nutrition and lifestyle support rather than treating appetite suppression as an isolated therapeutic objective.

Clinical Standards and Access Are Reshaping Oral Anorexiant Use

The landscape is being reshaped by stricter expectations for durable weight-management outcomes, cardiovascular and psychiatric safety, evidence of long-term tolerability, and appropriate prescribing. Regulators and health systems increasingly emphasize risk-benefit assessment, contraindication screening, post-market surveillance, and responsible communication of treatment benefits. Access is also influenced by reimbursement rules, shortages of healthcare professionals, diagnostic practices, and the growing role of telehealth and digital patient-support services.

Artificial Intelligence Strengthens Discovery, Safety, and Patient Support

Artificial intelligence can contribute across the oral anorexiant drug lifecycle by identifying biological targets, prioritizing compounds, analyzing clinical-trial data, and detecting potential safety signals in real-world evidence. In care delivery, validated tools may support patient identification, adherence reminders, adverse-event triage, and individualized counseling. These benefits depend on representative datasets, transparent validation, privacy safeguards, clinician oversight, and controls against algorithmic bias; AI should augment-not replace-medical judgment and regulatory review.

Regional Dynamics Reflect Different Burden, Regulation, and Care Capacity

North America combines substantial obesity-care demand with sophisticated specialty care, digital prescribing, and close scrutiny of safety, affordability, and insurance coverage. Latin America faces expanding chronic-disease needs alongside uneven reimbursement, supply access, and specialist availability. Europe emphasizes evidence-based prescribing, pharmacovigilance, health-technology assessment, and coordinated public-health policy. The Middle East is shaped by high metabolic-disease burden in several countries, investment in modern healthcare infrastructure, and varied regulatory pathways. Africa requires approaches suited to unequal diagnostic capacity, affordability constraints, and broader infectious- and noncommunicable-disease priorities. Asia-Pacific presents diverse conditions, from advanced clinical systems and aging populations to rapidly changing urban health patterns and uneven access across markets.

Economic and Security Groups Influence Policy Alignment and Access

ASEAN members face differing regulatory maturity, healthcare financing, and distribution capabilities, making regional coordination valuable while preserving national requirements. BRICS economies span large and diverse patient populations, domestic-manufacturing ambitions, and varied evidence and reimbursement systems. The European Union benefits from common regulatory coordination but retains national differences in health-technology assessment and payment. G7 countries generally maintain advanced research and pharmacovigilance capabilities while confronting affordability and health-system capacity pressures. GCC states can leverage concentrated healthcare investment and coordinated procurement, with attention to sustainable prescribing and local expertise. NATO members are not a uniform health-policy bloc, but many share resilience concerns involving pharmaceutical supply chains, emergency preparedness, and continuity of essential care.

Country Priorities Range from Innovation Capacity to Equitable Access

Australia emphasizes primary-care integration, safety monitoring, and geographically equitable access. Brazil must balance a large and diverse health system with public-sector affordability and regulatory oversight. Canada faces provincial variation in reimbursement and access alongside strong requirements for clinical evidence. China combines expanding chronic-disease needs with active regulatory modernization and domestic pharmaceutical capabilities. France and Germany place strong weight on clinical evidence, reimbursement assessment, and structured healthcare delivery. India’s priorities include affordability, manufacturing capacity, quality assurance, and access across highly varied care settings. Italy and Spain must address regional differences in health-system capacity and prescribing pathways. Japan emphasizes safety, aging-related care needs, and evidence suited to its healthcare system. Mexico faces uneven access, prevention needs, and regulatory and supply-chain considerations. Russia’s environment is shaped by domestic access, regulatory conditions, and supply resilience. South Korea combines advanced digital and clinical infrastructure with close regulatory oversight. The United Kingdom focuses on evidence appraisal, prescribing governance, and pressure on public healthcare capacity. The United States has extensive clinical research and specialist infrastructure but ongoing challenges involving coverage, affordability, appropriate use, and post-market safety monitoring.

Build Evidence-Led, Equitable, and Monitored Oral Anorexiant Strategies

Industry leaders should prioritize differentiated clinical value supported by well-designed trials, clinically meaningful endpoints, and sufficiently long follow-up. Safety programs should address cardiovascular, psychiatric, gastrointestinal, interaction, misuse, and discontinuation risks where relevant to a product’s profile. Development plans should include diverse populations and evidence that informs real-world prescribing. Companies and health systems should strengthen clinician education, transparent patient communication, adherence support, pharmacovigilance, and responsible supply planning. Partnerships with payers, regulators, primary-care networks, and patient organizations can improve appropriate access while reducing inappropriate demand and inequity.

Methodology: Triangulating Clinical, Regulatory, and Health-System Evidence

This executive summary uses a structured qualitative synthesis of the defined oral anorexiant drug scope and the required geographic and group frameworks. Analysis should triangulate peer-reviewed clinical literature, regulatory labeling and safety communications, clinical-trial registries, pharmacovigilance sources, public-health publications, reimbursement and health-technology-assessment documents, and national policy materials. Findings are organized by therapeutic change, AI application, region, economic or security grouping, and country. Claims should be retained only when supported by authoritative, current, and independently verifiable evidence; no market estimates, market shares, forecasts, or company-specific claims are used.

Sustainable Progress Depends on Clinical Value and Responsible Implementation

The oral anorexiant drug landscape is evolving toward more accountable chronic-care models in which efficacy, safety, durability, access, and patient support are assessed together. Regional and national differences make adaptable evidence and implementation strategies essential. Artificial intelligence may improve discovery and care coordination, but governance and clinical validation remain fundamental. Leaders that combine rigorous science, transparent risk management, equitable access, and health-system collaboration will be best positioned to support appropriate use and durable public-health value.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Oral Anorexiant Drug Market, by Product
7.1. Introduction
7.2. Branded
7.3. Generic
8. Oral Anorexiant Drug Market, by Mechanism Of Action
8.1. Introduction
8.2. GLP-1 Agonists
8.2.1. Long-Acting Agents
8.2.2. Short-Acting Agents
8.3. Lipase Inhibitors
8.4. Serotonin Agonists
9. Oral Anorexiant Drug Market, by Dosage Form
9.1. Introduction
9.2. Capsule
9.3. Oral Solution
9.4. Tablet
10. Oral Anorexiant Drug Market, by Indication
10.1. Introduction
10.2. Obesity
10.3. Overweight With Comorbidities
11. Oral Anorexiant Drug Market, by Patient Age Group
11.1. Introduction
11.2. Adult
11.3. Pediatric
12. Oral Anorexiant Drug Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacy
12.3. Online Pharmacy
12.4. Retail Pharmacy
13. Oral Anorexiant Drug Market, by Region
13.1. Introduction
13.2. Asia-Pacific
13.3. North America
13.4. Latin America
13.5. Europe
13.6. Middle East
13.7. Africa
14. Oral Anorexiant Drug Market, by Group
14.1. Introduction
14.2. ASEAN
14.3. GCC
14.4. European Union
14.5. BRICS
14.6. G7
14.7. NATO
15. Oral Anorexiant Drug Market, by Country
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. United Kingdom
15.7. Germany
15.8. France
15.9. Russia
15.10. Italy
15.11. Spain
15.12. China
15.13. India
15.14. Japan
15.15. Australia
15.16. South Korea
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. Market Concentration Analysis, 2025
16.2.1. Concentration Ratio (CR)
16.2.2. Herfindahl Hirschman Index (HHI)
16.3. Recent Developments & Impact Analysis, 2025
16.4. Product Portfolio Analysis, 2025
16.5. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Currax Pharmaceuticals LLC:
17.2. Dr. Reddy’s Laboratories Ltd
17.3. Eisai Co., Ltd.
17.4. Eli Lilly and Company
17.5. F. Hoffmann-La Roche Ltd
17.6. GlaxoSmithKline plc
17.7. Lupin Limited
17.8. Novo Nordisk A/S
17.9. Orexigen Therapeutics, Inc.
17.10. Sandoz International GmbH
17.11. Sun Pharmaceutical Industries Ltd
17.12. Teva Pharmaceutical Industries Ltd
17.13. Vivus, Inc.
18. Key Experts
LIST OF FIGURES
FIGURE 1. Global Oral Anorexiant Drug Market, Years Considered for the Study
FIGURE 2. Global Oral Anorexiant Drug Market, Research Design
FIGURE 3. Global Oral Anorexiant Drug Market, Research Framework
FIGURE 4. Global Oral Anorexiant Drug Market, Data Triangulation
FIGURE 5. Global Oral Anorexiant Drug Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Oral Anorexiant Drug Market Size, by Product, 2025 vs 2032 (%)
FIGURE 7. Global Oral Anorexiant Drug Market Size, by Product, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Oral Anorexiant Drug Market Size, by Mechanism Of Action, 2025 vs 2032 (%)
FIGURE 9. Global Oral Anorexiant Drug Market Size, by Mechanism Of Action, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Oral Anorexiant Drug Market Size, by Dosage Form, 2025 vs 2032 (%)
FIGURE 11. Global Oral Anorexiant Drug Market Size, by Dosage Form, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Oral Anorexiant Drug Market Size, by Indication, 2025 vs 2032 (%)
FIGURE 13. Global Oral Anorexiant Drug Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Oral Anorexiant Drug Market Size, by Patient Age Group, 2025 vs 2032 (%)
FIGURE 15. Global Oral Anorexiant Drug Market Size, by Patient Age Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Oral Anorexiant Drug Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 17. Global Oral Anorexiant Drug Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Oral Anorexiant Drug Market Size, by Region, 2025 vs 2032 (%)
FIGURE 19. Global Oral Anorexiant Drug Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global Oral Anorexiant Drug Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Oral Anorexiant Drug Market Size, by Country, 2025 vs 2032 (%)
FIGURE 22. Global Oral Anorexiant Drug Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 23. Global Oral Anorexiant Drug Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Oral Anorexiant Drug Market Segmentation & Coverage
TABLE 2. Global Oral Anorexiant Drug Market Size, 2017-2032 (USD Million)
TABLE 3. Global Oral Anorexiant Drug Market Size, by Product, 2017-2032 (USD Million)
TABLE 4. Global Branded Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Branded Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Branded Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Generic Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Generic Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Generic Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Oral Anorexiant Drug Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 11. Global GLP-1 Agonists Market Size, by Region, 2017-2032 (USD Million)
TABLE 12. Global GLP-1 Agonists Market Size, by Group, 2017-2032 (USD Million)
TABLE 13. Global GLP-1 Agonists Market Size, by Country, 2017-2032 (USD Million)
TABLE 14. Global Long-Acting Agents Market Size, by Region, 2017-2032 (USD Million)
TABLE 15. Global Long-Acting Agents Market Size, by Group, 2017-2032 (USD Million)
TABLE 16. Global Long-Acting Agents Market Size, by Country, 2017-2032 (USD Million)
TABLE 17. Global Short-Acting Agents Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Short-Acting Agents Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Short-Acting Agents Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Lipase Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Lipase Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Lipase Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global Serotonin Agonists Market Size, by Region, 2017-2032 (USD Million)
TABLE 24. Global Serotonin Agonists Market Size, by Group, 2017-2032 (USD Million)
TABLE 25. Global Serotonin Agonists Market Size, by Country, 2017-2032 (USD Million)
TABLE 26. Global Oral Anorexiant Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 27. Global Capsule Market Size, by Region, 2017-2032 (USD Million)
TABLE 28. Global Capsule Market Size, by Group, 2017-2032 (USD Million)
TABLE 29. Global Capsule Market Size, by Country, 2017-2032 (USD Million)
TABLE 30. Global Oral Solution Market Size, by Region, 2017-2032 (USD Million)
TABLE 31. Global Oral Solution Market Size, by Group, 2017-2032 (USD Million)
TABLE 32. Global Oral Solution Market Size, by Country, 2017-2032 (USD Million)
TABLE 33. Global Tablet Market Size, by Region, 2017-2032 (USD Million)
TABLE 34. Global Tablet Market Size, by Group, 2017-2032 (USD Million)
TABLE 35. Global Tablet Market Size, by Country, 2017-2032 (USD Million)
TABLE 36. Global Oral Anorexiant Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 37. Global Obesity Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Obesity Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Obesity Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Overweight With Comorbidities Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Overweight With Comorbidities Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Overweight With Comorbidities Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Oral Anorexiant Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 44. Global Adult Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global Adult Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global Adult Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global Pediatric Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global Pediatric Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global Pediatric Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global Oral Anorexiant Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 51. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 52. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 53. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 54. Global Online Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. Global Online Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 56. Global Online Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 57. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 58. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 59. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 60. Global Oral Anorexiant Drug Market Size, by Region, 2017-2032 (USD Million)
TABLE 61. Asia-Pacific Oral Anorexiant Drug Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. Asia-Pacific Oral Anorexiant Drug Market Size, by Product, 2017-2032 (USD Million)
TABLE 63. Asia-Pacific Oral Anorexiant Drug Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 64. Asia-Pacific Oral Anorexiant Drug Market Size, by GLP-1 Agonists, 2017-2032 (USD Million)
TABLE 65. Asia-Pacific Oral Anorexiant Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 66. Asia-Pacific Oral Anorexiant Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 67. Asia-Pacific Oral Anorexiant Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 68. Asia-Pacific Oral Anorexiant Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 69. North America Oral Anorexiant Drug Market Size, by Region, 2017-2032 (USD Million)
TABLE 70. North America Oral Anorexiant Drug Market Size, by Product, 2017-2032 (USD Million)
TABLE 71. North America Oral Anorexiant Drug Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 72. North America Oral Anorexiant Drug Market Size, by GLP-1 Agonists, 2017-2032 (USD Million)
TABLE 73. North America Oral Anorexiant Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 74. North America Oral Anorexiant Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 75. North America Oral Anorexiant Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 76. North America Oral Anorexiant Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 77. Latin America Oral Anorexiant Drug Market Size, by Region, 2017-2032 (USD Million)
TABLE 78. Latin America Oral Anorexiant Drug Market Size, by Product, 2017-2032 (USD Million)
TABLE 79. Latin America Oral Anorexiant Drug Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 80. Latin America Oral Anorexiant Drug Market Size, by GLP-1 Agonists, 2017-2032 (USD Million)
TABLE 81. Latin America Oral Anorexiant Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 82. Latin America Oral Anorexiant Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 83. Latin America Oral Anorexiant Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 84. Latin America Oral Anorexiant Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 85. Europe Oral Anorexiant Drug Market Size, by Region, 2017-2032 (USD Million)
TABLE 86. Europe Oral Anorexiant Drug Market Size, by Product, 2017-2032 (USD Million)
TABLE 87. Europe Oral Anorexiant Drug Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 88. Europe Oral Anorexiant Drug Market Size, by GLP-1 Agonists, 2017-2032 (USD Million)
TABLE 89. Europe Oral Anorexiant Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 90. Europe Oral Anorexiant Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 91. Europe Oral Anorexiant Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 92. Europe Oral Anorexiant Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 93. Middle East Oral Anorexiant Drug Market Size, by Region, 2017-2032 (USD Million)
TABLE 94. Middle East Oral Anorexiant Drug Market Size, by Product, 2017-2032 (USD Million)
TABLE 95. Middle East Oral Anorexiant Drug Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 96. Middle East Oral Anorexiant Drug Market Size, by GLP-1 Agonists, 2017-2032 (USD Million)
TABLE 97. Middle East Oral Anorexiant Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 98. Middle East Oral Anorexiant Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 99. Middle East Oral Anorexiant Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 100. Middle East Oral Anorexiant Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 101. Africa Oral Anorexiant Drug Market Size, by Region, 2017-2032 (USD Million)
TABLE 102. Africa Oral Anorexiant Drug Market Size, by Product, 2017-2032 (USD Million)
TABLE 103. Africa Oral Anorexiant Drug Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 104. Africa Oral Anorexiant Drug Market Size, by GLP-1 Agonists, 2017-2032 (USD Million)
TABLE 105. Africa Oral Anorexiant Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 106. Africa Oral Anorexiant Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 107. Africa Oral Anorexiant Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 108. Africa Oral Anorexiant Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 109. Global Oral Anorexiant Drug Market Size, by Group, 2017-2032 (USD Million)
TABLE 110. ASEAN Oral Anorexiant Drug Market Size, by Group, 2017-2032 (USD Million)
TABLE 111. ASEAN Oral Anorexiant Drug Market Size, by Product, 2017-2032 (USD Million)
TABLE 112. ASEAN Oral Anorexiant Drug Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 113. ASEAN Oral Anorexiant Drug Market Size, by GLP-1 Agonists, 2017-2032 (USD Million)
TABLE 114. ASEAN Oral Anorexiant Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 115. ASEAN Oral Anorexiant Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 116. ASEAN Oral Anorexiant Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 117. ASEAN Oral Anorexiant Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 118. GCC Oral Anorexiant Drug Market Size, by Group, 2017-2032 (USD Million)
TABLE 119. GCC Oral Anorexiant Drug Market Size, by Product, 2017-2032 (USD Million)
TABLE 120. GCC Oral Anorexiant Drug Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 121. GCC Oral Anorexiant Drug Market Size, by GLP-1 Agonists, 2017-2032 (USD Million)
TABLE 122. GCC Oral Anorexiant Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 123. GCC Oral Anorexiant Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 124. GCC Oral Anorexiant Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 125. GCC Oral Anorexiant Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 126. European Union Oral Anorexiant Drug Market Size, by Group, 2017-2032 (USD Million)
TABLE 127. European Union Oral Anorexiant Drug Market Size, by Product, 2017-2032 (USD Million)
TABLE 128. European Union Oral Anorexiant Drug Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 129. European Union Oral Anorexiant Drug Market Size, by GLP-1 Agonists, 2017-2032 (USD Million)
TABLE 130. European Union Oral Anorexiant Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 131. European Union Oral Anorexiant Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 132. European Union Oral Anorexiant Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 133. European Union Oral Anorexiant Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 134. BRICS Oral Anorexiant Drug Market Size, by Group, 2017-2032 (USD Million)
TABLE 135. BRICS Oral Anorexiant Drug Market Size, by Product, 2017-2032 (USD Million)
TABLE 136. BRICS Oral Anorexiant Drug Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 137. BRICS Oral Anorexiant Drug Market Size, by GLP-1 Agonists, 2017-2032 (USD Million)
TABLE 138. BRICS Oral Anorexiant Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 139. BRICS Oral Anorexiant Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 140. BRICS Oral Anorexiant Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 141. BRICS Oral Anorexiant Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 142. G7 Oral Anorexiant Drug Market Size, by Group, 2017-2032 (USD Million)
TABLE 143. G7 Oral Anorexiant Drug Market Size, by Product, 2017-2032 (USD Million)
TABLE 144. G7 Oral Anorexiant Drug Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 145. G7 Oral Anorexiant Drug Market Size, by GLP-1 Agonists, 2017-2032 (USD Million)
TABLE 146. G7 Oral Anorexiant Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 147. G7 Oral Anorexiant Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 148. G7 Oral Anorexiant Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 149. G7 Oral Anorexiant Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 150. NATO Oral Anorexiant Drug Market Size, by Group, 2017-2032 (USD Million)
TABLE 151. NATO Oral Anorexiant Drug Market Size, by Product, 2017-2032 (USD Million)
TABLE 152. NATO Oral Anorexiant Drug Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 153. NATO Oral Anorexiant Drug Market Size, by GLP-1 Agonists, 2017-2032 (USD Million)
TABLE 154. NATO Oral Anorexiant Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 155. NATO Oral Anorexiant Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 156. NATO Oral Anorexiant Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 157. NATO Oral Anorexiant Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 158. Global Oral Anorexiant Drug Market Size, by Country, 2017-2032 (USD Million)
TABLE 159. United States Oral Anorexiant Drug Market Size, 2017-2032 (USD Million)
TABLE 160. United States Oral Anorexiant Drug Market Size, by Product, 2017-2032 (USD Million)
TABLE 161. United States Oral Anorexiant Drug Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 162. United States Oral Anorexiant Drug Market Size, by GLP-1 Agonists, 2017-2032 (USD Million)
TABLE 163. United States Oral Anorexiant Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 164. United States Oral Anorexiant Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 165. United States Oral Anorexiant Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 166. United States Oral Anorexiant Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 167. Canada Oral Anorexiant Drug Market Size, 2017-2032 (USD Million)
TABLE 168. Canada Oral Anorexiant Drug Market Size, by Product, 2017-2032 (USD Million)
TABLE 169. Canada Oral Anorexiant Drug Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 170. Canada Oral Anorexiant Drug Market Size, by GLP-1 Agonists, 2017-2032 (USD Million)
TABLE 171. Canada Oral Anorexiant Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 172. Canada Oral Anorexiant Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 173. Canada Oral Anorexiant Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 174. Canada Oral Anorexiant Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 175. Mexico Oral Anorexiant Drug Market Size, 2017-2032 (USD Million)
TABLE 176. Mexico Oral Anorexiant Drug Market Size, by Product, 2017-2032 (USD Million)
TABLE 177. Mexico Oral Anorexiant Drug Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 178. Mexico Oral Anorexiant Drug Market Size, by GLP-1 Agonists, 2017-2032 (USD Million)
TABLE 179. Mexico Oral Anorexiant Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 180. Mexico Oral Anorexiant Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 181. Mexico Oral Anorexiant Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 182. Mexico Oral Anorexiant Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 183. Brazil Oral Anorexiant Drug Market Size, 2017-2032 (USD Million)
TABLE 184. Brazil Oral Anorexiant Drug Market Size, by Product, 2017-2032 (USD Million)
TABLE 185. Brazil Oral Anorexiant Drug Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 186. Brazil Oral Anorexiant Drug Market Size, by GLP-1 Agonists, 2017-2032 (USD Million)
TABLE 187. Brazil Oral Anorexiant Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 188. Brazil Oral Anorexiant Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 189. Brazil Oral Anorexiant Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 190. Brazil Oral Anorexiant Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 191. United Kingdom Oral Anorexiant Drug Market Size, 2017-2032 (USD Million)
TABLE 192. United Kingdom Oral Anorexiant Drug Market Size, by Product, 2017-2032 (USD Million)
TABLE 193. United Kingdom Oral Anorexiant Drug Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 194. United Kingdom Oral Anorexiant Drug Market Size, by GLP-1 Agonists, 2017-2032 (USD Million)
TABLE 195. United Kingdom Oral Anorexiant Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 196. United Kingdom Oral Anorexiant Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 197. United Kingdom Oral Anorexiant Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 198. United Kingdom Oral Anorexiant Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 199. Germany Oral Anorexiant Drug Market Size, 2017-2032 (USD Million)
TABLE 200. Germany Oral Anorexiant Drug Market Size, by Product, 2017-2032 (USD Million)
TABLE 201. Germany Oral Anorexiant Drug Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 202. Germany Oral Anorexiant Drug Market Size, by GLP-1 Agonists, 2017-2032 (USD Million)
TABLE 203. Germany Oral Anorexiant Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 204. Germany Oral Anorexiant Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 205. Germany Oral Anorexiant Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 206. Germany Oral Anorexiant Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 207. France Oral Anorexiant Drug Market Size, 2017-2032 (USD Million)
TABLE 208. France Oral Anorexiant Drug Market Size, by Product, 2017-2032 (USD Million)
TABLE 209. France Oral Anorexiant Drug Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 210. France Oral Anorexiant Drug Market Size, by GLP-1 Agonists, 2017-2032 (USD Million)
TABLE 211. France Oral Anorexiant Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 212. France Oral Anorexiant Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 213. France Oral Anorexiant Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 214. France Oral Anorexiant Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 215. Russia Oral Anorexiant Drug Market Size, 2017-2032 (USD Million)
TABLE 216. Russia Oral Anorexiant Drug Market Size, by Product, 2017-2032 (USD Million)
TABLE 217. Russia Oral Anorexiant Drug Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 218. Russia Oral Anorexiant Drug Market Size, by GLP-1 Agonists, 2017-2032 (USD Million)
TABLE 219. Russia Oral Anorexiant Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 220. Russia Oral Anorexiant Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 221. Russia Oral Anorexiant Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 222. Russia Oral Anorexiant Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 223. Italy Oral Anorexiant Drug Market Size, 2017-2032 (USD Million)
TABLE 224. Italy Oral Anorexiant Drug Market Size, by Product, 2017-2032 (USD Million)
TABLE 225. Italy Oral Anorexiant Drug Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 226. Italy Oral Anorexiant Drug Market Size, by GLP-1 Agonists, 2017-2032 (USD Million)
TABLE 227. Italy Oral Anorexiant Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 228. Italy Oral Anorexiant Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 229. Italy Oral Anorexiant Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 230. Italy Oral Anorexiant Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 231. Spain Oral Anorexiant Drug Market Size, 2017-2032 (USD Million)
TABLE 232. Spain Oral Anorexiant Drug Market Size, by Product, 2017-2032 (USD Million)
TABLE 233. Spain Oral Anorexiant Drug Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 234. Spain Oral Anorexiant Drug Market Size, by GLP-1 Agonists, 2017-2032 (USD Million)
TABLE 235. Spain Oral Anorexiant Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 236. Spain Oral Anorexiant Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 237. Spain Oral Anorexiant Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 238. Spain Oral Anorexiant Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 239. China Oral Anorexiant Drug Market Size, 2017-2032 (USD Million)
TABLE 240. China Oral Anorexiant Drug Market Size, by Product, 2017-2032 (USD Million)
TABLE 241. China Oral Anorexiant Drug Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 242. China Oral Anorexiant Drug Market Size, by GLP-1 Agonists, 2017-2032 (USD Million)
TABLE 243. China Oral Anorexiant Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 244. China Oral Anorexiant Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 245. China Oral Anorexiant Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 246. China Oral Anorexiant Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 247. India Oral Anorexiant Drug Market Size, 2017-2032 (USD Million)
TABLE 248. India Oral Anorexiant Drug Market Size, by Product, 2017-2032 (USD Million)
TABLE 249. India Oral Anorexiant Drug Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 250. India Oral Anorexiant Drug Market Size, by GLP-1 Agonists, 2017-2032 (USD Million)
TABLE 251. India Oral Anorexiant Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 252. India Oral Anorexiant Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 253. India Oral Anorexiant Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 254. India Oral Anorexiant Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 255. Japan Oral Anorexiant Drug Market Size, 2017-2032 (USD Million)
TABLE 256. Japan Oral Anorexiant Drug Market Size, by Product, 2017-2032 (USD Million)
TABLE 257. Japan Oral Anorexiant Drug Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 258. Japan Oral Anorexiant Drug Market Size, by GLP-1 Agonists, 2017-2032 (USD Million)
TABLE 259. Japan Oral Anorexiant Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 260. Japan Oral Anorexiant Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 261. Japan Oral Anorexiant Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 262. Japan Oral Anorexiant Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 263. Australia Oral Anorexiant Drug Market Size, 2017-2032 (USD Million)
TABLE 264. Australia Oral Anorexiant Drug Market Size, by Product, 2017-2032 (USD Million)
TABLE 265. Australia Oral Anorexiant Drug Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 266. Australia Oral Anorexiant Drug Market Size, by GLP-1 Agonists, 2017-2032 (USD Million)
TABLE 267. Australia Oral Anorexiant Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 268. Australia Oral Anorexiant Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 269. Australia Oral Anorexiant Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 270. Australia Oral Anorexiant Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 271. South Korea Oral Anorexiant Drug Market Size, 2017-2032 (USD Million)
TABLE 272. South Korea Oral Anorexiant Drug Market Size, by Product, 2017-2032 (USD Million)
TABLE 273. South Korea Oral Anorexiant Drug Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 274. South Korea Oral Anorexiant Drug Market Size, by GLP-1 Agonists, 2017-2032 (USD Million)
TABLE 275. South Korea Oral Anorexiant Drug Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 276. South Korea Oral Anorexiant Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 277. South Korea Oral Anorexiant Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 278. South Korea Oral Anorexiant Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 279. Global Oral Anorexiant Drug Market Share, by Key Player, 2025
TABLE 280. Global Oral Anorexiant Drug Market, Key Experts

Companies Mentioned

  • Currax Pharmaceuticals LLC:
  • Dr. Reddy’s Laboratories Ltd
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc
  • Lupin Limited
  • Novo Nordisk A/S
  • Orexigen Therapeutics, Inc.
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceutical Industries Ltd
  • Vivus, Inc.

Related Topics

Related Reports

Catecholamines Anorexiant Drug Market - Global Forecast 2026-2032 - Product Image

Catecholamines Anorexiant Drug Market - Global Forecast 2026-2032

  • Report
  • 185 Pages
  • Global
From
Anorexiants - Global Strategic Business Report - Product Image

Anorexiants - Global Strategic Business Report

  • Report
  • 273 Pages
  • Global
From
Anorexiants Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031 - Product Image

Anorexiants Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

  • Report
  • 186 Pages
  • Global
From
Anorexiants Market Outlook 2026-2034: Market Share and Growth Analysis by Drug Class (GLP-1 Receptor Agonists, Sympathomimetic Amines, Combination Therapies, Serotonin-2C Agonists, Others), Route of Administration, Patient Demographics, Distribution Channel - Product Image

Anorexiants Market Outlook 2026-2034: Market Share and Growth Analysis by Drug Class (GLP-1 Receptor Agonists, Sympathomimetic Amines, Combination Therapies, Serotonin-2C Agonists, Others), Route of Administration, Patient Demographics, Distribution Channel

  • Report
  • 160 Pages
  • Global
From
Anorexiants - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Anorexiants - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 120 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.